Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Immune cell combo shows promise in tough brain cancer trial

NCT ID NCT00807027

First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 28 times

Summary

This study tested whether adding an immune cell therapy called Immuncell-LC to standard chemotherapy (temozolomide) helps people with newly diagnosed glioblastoma, an aggressive brain cancer. 180 adults in Korea took part. The goal was to see if the combination improved how long the cancer stayed under control and overall survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Gyunghee University Medical Center

    Seoul, South Korea

  • Hanyang University Guri Hospital

    Guri-si, Gyeonggi-do, South Korea

  • Konkuk University

    Seoul, South Korea

  • Korea University Anam Hospital

    Seoul, South Korea

  • Samsung Seoul Medical Center

    Seoul, South Korea

  • Seoul Asan Medical Center

    Seoul, South Korea

  • Yeonsei University Medical Center

    Seoul, South Korea

Conditions

Explore the condition pages connected to this study.